Epidemiology, Definition, and Electrocardiographic Characteristics of Supraventricular Tachycardia (SVT)

Definition and Mechanistic Overview

• Supraventricular tachycardia is defined as any abnormally rapid heart rhythm (> 100 beats/min at rest) that originates at or above the atrioventricular (AV) node, characterized by sudden onset and termination, with typical rates of 150–300 beats/min. 1
• The SVT spectrum includes atrioventricular nodal re‑entrant tachycardia (the most common subtype), atrioventricular reciprocating tachycardia (involving accessory pathways), atrial tachycardia (focal or multifocal), macro‑reentrant atrial tachycardia (e.g., typical atrial flutter), and junctional tachycardia. 1
• By definition, SVT excludes atrial fibrillation and sinus tachycardia, and its episodes begin and end abruptly, distinguishing it from the gradual acceleration/deceleration of sinus tachycardia. 1

Epidemiology

• The estimated prevalence of SVT in the general population is 2.25 per 1,000 individuals. 2
• The incidence is 35 new cases per 100,000 person‑years. 2
• The mean age at first presentation is 57 years (range from infancy to > 90 years). 2
• Women have twice the risk of developing SVT compared with men (relative risk ≈ 2.0). 2
• In patients with “lone” SVT (no structural heart disease), the mean age at onset is 37 years, whereas those with concomitant cardiovascular disease present at a mean age of 69 years. 2

Electrocardiographic (ECG) Features

• After the initial 10–20 beats, the rhythm becomes extremely regular, resembling a metronome; rates are typically 260–300 beats/min in infants and 150–300 beats/min in adults. 3
• In infants, a heart rate exceeding 230 beats/min strongly favors SVT over sinus tachycardia, which usually remains below this threshold. 3
• The regularity of R‑R intervals persists throughout the episode, providing a key diagnostic clue. 3
• P‑waves are identifiable in only about 60 % of SVT episodes, and when present, their morphology differs from sinus P‑waves. 3
• The QRS complex is typically identical to that of sinus rhythm; ventricular aberrancy is uncommon in infants, occurring in roughly 3 % of cases. 3

Understanding and Managing Supraventricular Tachycardia (SVT)

Definition and Characteristics

• Supraventricular tachycardia (SVT) is an abnormal heart rhythm that originates in the upper chambers of the heart (the atria) or in the electrical wiring between the upper and lower chambers, characterized by sudden episodes of very rapid, regular heartbeats—typically 150-300 beats per minute—that start and stop abruptly 4, 5
• The American College of Cardiology notes that SVT involves an extra electrical pathway or a loop in the heart's wiring system that allows electrical signals to circle around repeatedly, causing the heart to beat very fast 6
• Most people with SVT have structurally normal hearts—there's nothing wrong with the heart muscle itself, just the electrical system 4

Clinical Presentation

• Patients with SVT typically experience shortness of breath 5
• Fatigue or weakness is also a common symptom 5
• The American College of Cardiology states that about 15% of patients may experience fainting, particularly when episodes first start 4, 6

Diagnosis and Evaluation

• The American College of Cardiology recommends that your doctor capture the rhythm on an ECG (heart tracing) during an episode to confirm the diagnosis and determine the specific type of SVT 4, 7
• An echocardiogram (ultrasound of the heart) may be done to ensure there's no underlying structural heart problem 4, 7

Treatment and Management

• The American College of Cardiology suggests that vagal maneuvers (bearing down, holding your breath, or putting your face in ice water) can sometimes stop episodes 7
• The American Heart Association, as published in Circulation, notes that medications given in the emergency department (like adenosine) can terminate episodes immediately 5

Special Considerations

• The American College of Cardiology warns that if you have SVT with certain ECG patterns (called pre-excitation or Wolff-Parkinson-White syndrome), you need prompt evaluation by a heart rhythm specialist due to potential risks 7, 8
• The European Heart Journal states that the rhythm is extremely regular—like a metronome—after the first few beats 9, 10

Distinguishing Paroxysmal Supraventricular Tachycardia (PSVT) from Ventricular Tachycardia (VT)

Definitions and Mechanisms

• PSVT originates at or above the His bundle and produces narrow QRS complexes (<120 ms) with rates of 150–250 bpm, whereas VT originates from ventricular myocardium, generates wide QRS complexes (≥120 ms) and carries a markedly higher mortality risk. (American Heart Association) 11
• The most common PSVT mechanisms are re‑entry circuits: atrioventricular nodal re‑entrant tachycardia (AVNRT) and atrioventricular reciprocating tachycardia (AVRT) using accessory pathways. (American Heart Association) 12

ECG Diagnostic Criteria

• A narrow QRS (<120 ms) in the absence of pre‑existing bundle‑branch block strongly favors PSVT. (American Heart Association) 11
• A wide QRS (≥120 ms) strongly suggests VT; specific markers include AV dissociation or fusion beats, an R‑S interval >100 ms in any precordial lead, an initial R wave in aVR or an R/Q ratio >40 ms in aVR, concordant QRS polarity in leads V1‑V6, and a notch on the descending limb of a predominantly negative QRS in aVR. (American Heart Association) 11

Clinical Presentation

• Patients with PSVT commonly report palpitations (≈86 %), chest discomfort (≈47 %), and dyspnea (≈38 %); syncope occurs in about 15 % of cases, usually at onset or abrupt termination of the tachycardia. (American Heart Association) 12
• Polyuria may accompany PSVT episodes due to atrial natriuretic peptide release. (American Heart Association) 12
• In structurally normal hearts PSVT is generally benign, but prolonged episodes can lead to tachycardia‑mediated cardiomyopathy. (American Heart Association) 12

Acute Management

• For hemodynamically stable PSVT, vagal maneuvers (e.g., modified Valsalva) are first‑line, achieving conversion in ~43 % of attempts; if ineffective, intravenous adenosine converts ~91 % of cases. (American Heart Association) 11
• Synchronized cardioversion is reserved for hemodynamically unstable PSVT. (American Heart Association) 11
• Hemodynamically unstable VT requires immediate synchronized cardioversion. (American Heart Association) 11
• Adenosine, calcium‑channel blockers, or β‑blockers should never be used as first‑line therapy for wide‑complex tachycardia of uncertain origin because they may be harmful if the rhythm is VT. (American Heart Association) 11

Diagnostic Pitfalls

• When confronted with a wide‑complex tachycardia (QRS ≥120 ms), clinicians should assume VT until proven otherwise. (American Heart Association) 11
• The presence of AV dissociation or fusion complexes on the ECG confirms VT. (American Heart Association) 11

Long‑Term Management

• Catheter ablation is the first‑line definitive therapy for recurrent symptomatic PSVT, achieving success rates of 94–99 %. (American Heart Association) 11
• A low threshold for referral to electrophysiology for an invasive study is recommended in patients with recurrent PSVT. (American Heart Association) 12